TGX-221 is a potent phosphoinositide 3-kinase (PI3K)β inhibitor that has great therapeutic potential to treat prostate cancer. Chemical modification of TGX-221 at positions 2 and 9 was made. Five new TGX-221 analogs with different heterocyclic substituents of morpholine, 1-methylpiperazine, aniline, and thiazole-2-amine at positions 2 and 9 were synthesized. Parallel synthetic methods were employed in S N 2 replacement reactions at positions 2 and 9 of TGX-221.
Introduction
TGX-221 {7-methyl-2-morpholino-9-(1-(phenylamino)ethyl)-4H-pyrido[1,2-a]pyrimidin-4-one} is a potent phosphoinositide 3-kinase (PI3K)β inhibitor [1 -4] . Its key chemical features include a pyridopyrimidinone nucleus (I), a morpholinyl substituent at position 2 (II) and a 1-phenylaminoethyl moiety at position 9 (III) as shown in Fig. 1 [2] . Following on earlier reports of the PI3Kβ -inhibiting ability of TGX-221, structural modifications on TGX-221 were carried out. On the core structure of TGX-221, replacement of the pyridopyrimidinone nucleus was made [5 -8] . Two families of imidazopyrimidinones and triazolopyrimidinones were generated [5, 6] . Both series of the compounds were found to display high clearance in metabolism [7, 8] . Therefore two series of pyrazolopyrimidines and thiazolopyrimidinones were synthesized in an attempt to improve clearance [7, 8] . On the side fragment of TGX-221, a hydroxyethyl moiety was added to the aniline group at position 9 to produce analogs [9, 10] .
In this paper chemical modifications of TGX-221 at positions 2 and 9 were undertaken. The group at position 2 was replaced by 1-methylpiperazine and morpholine. The moiety at position 9 was substituted with thiazole-2-amine, 1-methylpiperazine and aniline. Five new TGX-221 analogs were synthesized. Parallel synthetic methods were employed in S N 2 replacement reactions.
Results and Discussion
The synthesis of TGX-221 analogs was initiated from 2-amino-3-bromo-5-methylpyridine and malonyl dichloride to generate the scaffold of 9-bromo-2-hydroxy-7-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (1). The hydroxyl group at position 2 of compound 1 was substituted with morpholine or 1-methylpiperazine. Subsequent replacement at position 9 of the resulting compounds was made with 1-methyl-piperazine, aniline or thiazole-2-amine. The synthetic procedures are illustrated in Scheme 1.
Compound 1 was formed through a nucleophilic cyclization reaction by treatment of malonyl dichloride with a solution of 2-amino-3-bromo-5-methylpyridine in dichloromethane (CH 2 Cl 2 ). The hydroxyl group in compound 1 was substituted with morpholine and 1-methylpiperazine through parallel synthesis to produce compounds 2 and 5, respectively. The bromo group in compound 2 was transformed to an acetyl group to afford compound 3 through an intramolecular Heck reaction. Using the same method compound 6 was generated from compound 5. The ketone group in compound 3 was reduced to the secondary alcohol by sodium borohydride (NaBH 4 ) to afford compound 4. Compound 7 was obtained in the same manner from compound 6.
Parallel synthesis was employed for the S N 2 reaction to replace the secondary alcohol in compounds 4 and 7 with thiazole-2-amine, 1-methylpiperazine and aniline to yield five compounds of TGX-221 analogs, as shown in Scheme 1. Analogs TGX-221a and TGX221b were generated from compound 4; analogs TGX221c, TGX-221d and TGX-221e were synthesized from compound 7. The new TGX-221 analogs were characterized by 1 H and 13 C NMR spectra and highresolution mass spectrometry.
A series of pyridopyrimidinone was reported in the patent by Jackson and co-workers [1] . In their patent, pyridinyl and morpholino groups were used as substituents at position 2 of the pyridopyrimidinone nucleus [1] . Some substituents, such as benzyl, 4-hydroxyphenylamino, pyridin-4-yl-ethyl and thiophene-2-yl-methyl were employed at position 9 [1] . The hydroxylethyl moiety was added to the aniline group at position 9 of TGX-221 [9, 10] . In our work, modifications of TGX-221 at positions 2 and 9 were undertaken. All analogs contain aminosubstituted heterocyclic moieties as substituents. 1-Methylpiperazine and morpholine rings were used as substituents at position 2. Thiazole-2-amine, 1-methylpiperazine and aniline were selected as substituents at position 9. Combination of the substituents generated five new TGX-221 analogs. Four analogs with the 1-methylpiperazine group are particularly attractive, since 1-methylpiperazine possesses a protonatable nitrogen atom which will enable the formation of more water-soluble acid addition salts, such as hydrochlorides.
We developed a synthetic procedure for TGX-221 analogs which is different from the previous synthetic method for a series of pyridopyrimidinone in Jackson's patent [1] . In our work, a microwave synthesizer was used to speed up the S N 2 replacement reactions from compound 1 to compounds 2 and 5. We employed two reaction steps to achieve the formation of the final compounds via compounds 3 and 6, which made methylation and S N 2 replacement reactions to proceed easily. Our synthesis is facile, proceeds from commercially available materials, is easily scaled up, and very manageable in relation to the synthesis of analogs. Morpholine and 1-methylpiperazine groups at position 2 are installed by a nucleophilic displacement reaction. 1-Methylpiperazine, aniline and thiazole-2-amine moieties at position 9 are installed by a S N 2 reaction.
Conclusion
Chemical modification of TGX-221 was carried out. 9-Bromo-2-hydroxy-7-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one was synthesized as the scaffold. Five new TGX-221 analogs were synthesized. Parallel synthetic methods were developed for S N 2 replacement of the hydroxyl group at positions 2 and 9 of the scaffold.
Experimental Section
Reactions that required an inert atmosphere were carried out under argon with flame-dried glassware. Column chromatography was carried out by employing silica gel (230 -400 mesh). Thin-layer chromatography (TLC) was performed on a silica gel w/uv254 uniplate TM . Parallel synthesis was conducted on Mettler Toledo MiniBlock and MiniBlock XT. Anhydrous organic solvents were purchased. Melting points were determined using a Barnstead International MET-TEMP ® capillary Melting Point Apparatus, Model 1001D-120VAC. IR spectra were measured with a Perkin Elmer TM Spectrum One FT-IR spectrometer. 1 H and 13 C NMR spectra were recorded on a 400 MHz spectrometer (400 and 100 MHz, respectively), or a 500 MHz spectrometer (500 and 125.5 MHz, respectively). Abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. High-resolution mass spectra (HRMS) were obtained on a double-focusing mass spectrometer.
Procedures for the synthesis of intermediates 1-7
Compounds 1, 2, and 3 were synthesized following the procedures given in refs. [1, 2] .
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Scheme 1. Synthesis of TGX-221 analogs.
9-Bromo-2-hydroxy-7-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (1)
To a solution of 2-amino-3-bromo-5-methylpyridine (2.25 g, 12 mmol) in CH 2 Cl 2 (25 mL) was added malonyl dichloride (1.25 mL, 12. 
9-Bromo-7-methyl-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (2)
To a suspension of compound 1 (1.275 g, 5 mmol) in CH 2 Cl 2 (30 mL) were added triethylamine (1.4 mL, 10 mmol) and methanesulfonyl chloride (0.54 mL, 7 mmol) at 0 • C. The mixture was stirred at room temperature for 30 min. Morpholine (1.25 mL, 12.5 mmol) was added, and the mixture was heated in a microwave synthesizer at 90 • C for 45 min. The mixture was diluted with water (30 mL) and extracted with CH 2 Cl 2 (3 × 100 mL). The organic layer was washed with water and dried over Na 2 SO 4 . After concentration under reduced pressure, the dark-yellow residue was purified through a silica flash column using EtOAc/hexane 
9-Acetyl-7-methyl-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (3)
Compound 2 (650 mg, 2 mmol) in DMF (10 mL) was mixed with N,N-diisopropylethylamine (1.5 mL), butyl vinyl ether (1.6 mL) and dichloro-1,1 -bis(diphenylphosphino)ferrocene palladium(II) (70 mg, 0.066 mmol) at room temperature under argon for 30 min until a homogeneous solution was formed. The solution was heated to 120 • C for 16 h. After cooling, the solution was poured into 100 mL of 1 M HCl aqueous solution at 0 • C. The mixture was stirred at room temperature overnight and extracted with CH 2 Cl 2 (2 × 100 mL). The combined organic phases were washed with water and dried over Na 2 SO 4 . Removal of the solvent under reduced pressure followed by purification of the resulting residue through a silica flash column using EtOAc/hexanes 3 : 1 as an eluent afforded compound 3 as a yellow solid with a yield of 60 % (389 mg). M. p. 207 -208 • C. 
9-(1-Hydroxyethyl)-7-methyl-2-morpholino-4H-pyrido-[1,2-a]pyrimidin-4-one (4)
Sodium borohydride (52.2 mg, 1.38 mmol) was added to a suspension of compound 3 (198 mg, 0.69 mmol) in CH 2 Cl 2 (5 mL) and methanol (10 mL) at 0 • C. The reaction mixture was stirred for 2 h at room temperature. Water was added and the mixture extracted with chloroform (3 × 30 mL). The organic layer was washed with water and dried over Na 2 SO 4 . After concentration under reduced pressure, the residue was crystallized in EtOAc/hexane (1:1) to obtain compound 4 as a colorless solid with a yield of 75 % (150 mg). M. p. 218 -219 • C. 
9-Bromo-7-methyl-2-(4-methylpiperazin-1-yl)-4H-pyrido-[1,2-a]pyrimidin-4-one (5)
To a suspension of compound 2 (600 mg, 2.35 mmol) in CH 2 Cl 2 (30 mL) was added triethylamine (1.5 mL, 7.06 mmol), followed by methanesulfonyl chloride (0.4 mL, 4.7 mmol) at 0 • C. The mixture was stirred at room temperature for 1 h. 1-Methylpiperazine (1.1 mL, 7.06 mmol) was added, and the mixture was heated in a microwave synthesizer at 90 • C for 45 min. The mixture was diluted with water (30 mL) and extracted with CH 2 Cl 2 (3 × 100 mL). The organic layer was washed with water and dried over Na 2 SO 4 . After concentration under reduced pressure, the dark-yellow residue was purified through a silica flash column using 1 % MeOH/CH 2 Cl 2 as an eluent to give compound 5 as a paleyellow solid with a yield of 43 % (0.45 g). M. p. 201 -202 • C. 
9-Acetyl-7-methyl-2-(4-methylpiperazin-1-yl)-4H-pyrido-[1,2-a]pyrimidin-4-one (6)
Compound 5 (328 mg, 1.0 mmol) in DMF (10 mL) was mixed with N,N-diisopropylethylamine (0.8 mL), butyl vinyl ether (0.4 mL, 4 mmol) and dichloro-1,1 -bis(diphenylphosphino)ferrocene palladium(II) (70 mg, 0.05 mmol) at room temperature under argon for 30 min until a homogeneous solution was formed. The solution was heated to 120 • C for 1 h in a microwave synthesizer. After cooling, the solution was poured into 100 mL of a 1 M HCl aqueous solution at 0 • C. The mixture was stirred at room temperature overnight and extracted with CH 2 Cl 2 (2 × 100 mL). The combined organic phases were washed with water and dried over Na 2 SO 4 . Removal of the solvent under reduced pressure followed by purification of the resulting residue through a silica flash column using 1 % MeOH/CHCl 3 as an eluent afforded compound 6 as a yellow solid with a yield of 60 % (192 mg 
9-(1-Hydroxyethyl)-7-methyl-2-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one (7)
Sodium borohydride (100 mg, 1.32 mmol) was added to a suspension of compound 6 (200 mg, 0.66 mmol) in CH 2 Cl 2 (5 mL) and methanol (10 mL) at 0 • C. The reaction mixture was stirred for 3 h at room temperature. Water was added and extracted with chloroform (3 × 30 mL). The organic layer was washed with water and dried over Na 2 SO 4 . After concentration under reduced pressure, the residue was purified by column chromatography with 2 % MeOH/CHCl 3 as an eluent to obtain compound 7 as a colorless solid with a yield of 78 % ( 
General procedure for the parallel synthesis of TGX-221a-e
Parallel synthesis was carried out in five reactors on a Mettler Toledo MiniBlock for the S N 2 reaction to replace the secondary alcohol in compounds 4 and 7 with thiazole-2-amine, 1-methylpiperazine and aniline. Triethylamine and methanesulfonyl chloride were added to the solution of compounds 4 and 7 in CH 2 Cl 2 at 0 • C, respectively. The mixtures were stirred at room temperature for 1 h. When the methylation reactions were completed, thiazole-2-amine, 1-methylpiperazine and aniline were added to the obtained solutions of methylated compounds 4 and 7, respectively. After the mixtures were refluxed for 24 h, the solutions were diluted with CH 2 Cl 2 (30 mL). The organic layer was washed with water and dried over Na 2 SO 4 . Removal of the solvent under reduced pressure followed by purification of the resulting residue through a silica flash column using MeOH/CH 2 Cl 2 as an eluent produced the five analogs TGX-221a-e.
